CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; none of the 25 sources its claims cite is checked for support yet.

Axonal Transport, Amyloid Precursor Protein, Kinesin-1, and the Processing Apparatus: Revisited

Open access

Abstract

The sequential enzymatic actions of β-APP cleaving enzyme 1 (BACE1), presenilins (PS), and other proteins of the γ-secretase complex liberate β-amyloid (Aβ) peptides from larger integral membrane proteins, termed β-amyloid precursor proteins (APPs). Relatively little is known about the normal function(s) of APP or the neuronal compartment(s) in which APP undergoes proteolytic processing. Recent studies have been interpreted as consistent with the idea that APP serves as a kinesin-1 cargo receptor and that PS and BACE1 are associated with the APP-resident membranous cargos that undergo rapid axonal transport. In this report, derived from a collaboration among several independent laboratories, we examined the potential associations of APP and kinesin-1 using glutathione S-transferase pull-down and coimmunoprecipitation assays. In addition, we assessed the trafficking of membrane proteins in the sciatic nerves of transgenic mice with heterozygous or homozygous deletions of APP. In contrast to previous reports, we were unable to find evidence for direct interactions between APP and kinesin-1. Furthermore, the transport of kinesin-1 and tyrosine kinase receptors, previously reported to require APP, was unchanged in axons of APP-deficient mice. Finally, we show that two components of the APP proteolytic machinery, i.e., PS1 and BACE1, are not cotransported with APP in the sciatic nerves of mice. These findings suggest that the hypothesis that APP serves as a kinesin-1 receptor and that the proteolytic processing machinery responsible for generating Aβ is transported in the same vesicular compartment in axons of peripheral nerves requires revision.

Overview

CoChat Summary

TL;DR

This multi-laboratory study re-examined whether APP serves as a kinesin-1 cargo receptor and whether the APP processing machinery is cotransported in axons. It found no evidence for direct APP–kinesin-1 interaction or for cotransport of PS1/BACE1 with APP in mouse peripheral nerve, and axonal transport of kinesin-1 and Trk was unchanged in APP-deficient mice.

Key findings

  • GST pull-down assays showed that TR-containing GST-KLC1 constructs bound GFP-AID, but also bound GFP alone, APLP1/APLP2 intracellular domains, Fe65, and PAT1a; in vitro-translated or heterologously expressed KLC1 did not bind GST-AID, whereas Fe65 and Numb did. The authors conclude the TR-domain binding is nonspecific and not evidence for a direct APP–kinesin-1 interaction.
  • In mouse brain, APP did not cofractionate with kinesin-1: APP was primarily in V0/V1 fractions, whereas KHC and KLC were in all vesicle fractions including V2. APP also did not coimmunoprecipitate with multiple KHC or KLC antibodies, and kinesin-1 did not coimmunoprecipitate with APP antibodies; JIP3/SYD did coimmunoprecipitate with kinesin-1, with ~1% of total JIP3 cofractionating, validating the conditions.
  • In sciatic nerves from 5-month-old wild-type, APP heterozygous knockout, APP homozygous knockout, and APPswe/Tg2576 mice, steady-state levels of KHC, dynein, synaptophysin, neurofilament, and β-tubulin were unchanged. After 24 h ligation, accumulation of KHC, KLC, Trk, and PS1 in proximal segments was comparable across APP genotypes, indicating APP-independent transport of kinesin-1 and Trk.
  • PS1 was not cotransported with APP: after 6 h double ligation, APP accumulated proximal to the ligature, but PS1-NTF did not. BACE1 and Aβ were undetectable in sciatic nerve, including the proximal segment of APPswe mice, whereas BACE1 was detected as an ~70 kDa species in hippocampus and Aβ was detected in APPswe N2a cells and APPswe cortex.

Methods

  • Six laboratories collaborated. The study used GST pull-down assays with recombinant KLC1, APP, APLP1, and APLP2 constructs plus in vitro transcription-translation; coimmunoprecipitation, immunodepletion, Western blotting, and vesicle fractionation from mouse brain.
  • Mouse models included wild-type, APP heterozygous and homozygous knockout, APPswe/Tg2576, and BACE1-deficient mice, all at 5 months of age. Sciatic nerves were ligated for 6 or 24 h or crushed, and ~0.3 cm proximal and distal segments were analyzed by Western blot and immunohistochemistry.
  • Main analyses were SDS-PAGE/Western blot, autoradiography, and confocal immunofluorescence; each presented experiment was repeated at least three times.

Limitations

  • The paper states that APP and kinesin-1 could still interact indirectly through a linker protein such as JIP1b, but notes that such data are based only on in vitro analyses and need in vivo support.
  • The paper states that secretases may be transported in axons at levels too low to detect, and that the findings in peripheral nerve may not apply to CNS neurons, where APP and secretase levels may be sufficient to generate Aβ.
  • The paper considers it unlikely but acknowledges that abundant PS1 from cells intrinsic to the nerve could mask small amounts of axonally transported PS1; more broadly, the text makes evident that this is a negative/absence-of-detection study relying on antibody sensitivity and specificity, without live transport imaging or rescue experiments.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1523/jneurosci.3089-04.2005

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Nonspecific binding of AID and GST-KLC1 fusion proteins containing TRs. A , Schematic representation of GST-KLC1 deletion mutants used in GST pull-down assays. For details, see Materials and Methods. B , Pull-down assays show that all GST-KLC constructs containing two or more TRs bind to in vitro -translated GFP-AID constructs and with lower affinity to the GFP-only control. Neither GST alone nor GST-KLC-CC (both lacking TRs) pulled down GFP-AID or GFP. The fact that TR-containing constructs pulled down both GFP-AID and to a lower extent the highly soluble protein GFP suggests that these are nonspecific proteinprotein interactions. C , In addition to GFP-AID, both GFP-ALID1 and GFP-ALID2 were retained to a very similar extent on GSTKLC 𝚫 CT. Identical results were obtained with GST-KLC-TR or GST-KLC-CC/TR beads (data not shown). D , Schematic representation of GFP-APP intracellular domain deletion mutants used in GST pull downs (see Materials and Methods). E , GST-KLC-CC/TR binds with similar affinities to GFP-AID and GFP-AID constructs with deletions of the BaSS (G-AID 𝚫 B), PEER (G-AID 𝚫 P), or NPTY (G-AID 𝚫 N) domains of APP. These represent domains that have been shown previously to affect trafficking of APP and map to the domain proposed by Kamal et al. (2000) to bind TR domain in KLC1. F , Beads containing GST-KLC with TR domains also pull down recombinant Fe65 with high affinity, again suggesting nonspecific binding of TR domains to proteins in this assay system. G , GST pull downs with GST fused to the intracellular domain of APP demonstrated binding to the known APP interacting proteins Fe65 and Numb, whereas no binding of KLC1 was observed under identical conditions.
Figure 1 Nonspecific binding of AID and GST-KLC1 fusion proteins containing TRs. A , Schematic representation of GST-KLC1 deletion mutants used in GST pull-down assays. For details, see Materials and Methods. B , Pull-down assays show that all GST-KLC constructs containing two or more TRs bind to in vitro -translated GFP-AID constructs and with lower affinity to the GFP-only control. Neither GST alone nor GST-KLC-CC (both lacking TRs) pulled down GFP-AID or GFP. The fact that TR-containing constructs pulled down both GFP-AID and to a lower extent the highly soluble protein GFP suggests that these are nonspecific proteinprotein interactions. C , In addition to GFP-AID, both GFP-ALID1 and GFP-ALID2 were retained to a very similar extent on GSTKLC 𝚫 CT. Identical results were obtained with GST-KLC-TR or GST-KLC-CC/TR beads (data not shown). D , Schematic representation of GFP-APP intracellular domain deletion mutants used in GST pull downs (see Materials and Methods). E , GST-KLC-CC/TR binds with similar affinities to GFP-AID and GFP-AID constructs with deletions of the BaSS (G-AID 𝚫 B), PEER (G-AID 𝚫 P), or NPTY (G-AID 𝚫 N) domains of APP. These represent domains that have been shown previously to affect trafficking of APP and map to the domain proposed by Kamal et al. (2000) to bind TR domain in KLC1. F , Beads containing GST-KLC with TR domains also pull down recombinant Fe65 with high affinity, again suggesting nonspecific binding of TR domains to proteins in this assay system. G , GST pull downs with GST fused to the intracellular domain of APP demonstrated binding to the known APP interacting proteins Fe65 and Numb, whereas no binding of KLC1 was observed under identical conditions.CC-BY-NC-SA · From the PDF
Figure 2 Kinesin-1 and APP do not cofractionate or coimmunoprecipitate from brain lysate. A , Subcellular fractionation of mouse brain was performed as described previously (Morfini et al., 2002) to generate three vesicle fractions (V0, V1, and V2) and a cytosolic fraction (Cyt). Under the conditions of fractionation, KHCs and KLCs are found in all fractions, but KLCs exhibit differences in stoichiometry and isoform composition. In contrast, APP immunoreactivity is associated primarily with V0 and V1 fractions, with only trace amounts in V2 and low levels in the cytosol. V2 contains high levels of KHC, KLC1, KLC2, synaptophysin (P38), and synapsin I. This suggests that kinesin-1 and APP do not cofractionate in mouse brain. B , Immunoprecipitates of kinesin-1 from mouse brain show that Coomassie blue-stained levels of kinesin-1 heavy chain are obtained (CB), but no band corresponding to APP was seen. Immunoblots of whole-brain lysate show that kinesin-1 heavy chain (H2) is readily resolved from APP (22C11) in this gel system. These are distinguishable even when a mixture of both antibodies (H2 + 22C11) is used for immunoblotting. C , Immunoprecipitation of kinesin-1 from mouse brain using antibodies against either kinesin-1 heavy chains (SUK4 or H2) or light chains (63-90, L1, L2, or KLC-All) precipitated both KHC and KLC subunits (Pfister et al., 1989; Stenoien and Brady, 1997). Nevertheless, APP could not be detected in immunoprecipitates using kinesin-1 antibodies. Brain lysate (L) was a positive control. Negative controls, i.e., protein G beads without primary antibodies (B) or with normal mouse IgG show immunoprecipitation specificity. Similarly, kinesin-1 subunits were not detectable in immunoprecipitates with APP antibodies [Ct-APP and JH; see KHC (H2) for kinesin-1 heavy chain, KLC (63-90) for kinesin-1 light chain]. Antigens in immunoprecipitates were visualized using specific antibodies against kinesin-1 subunits (H2 or 63-90) or APP (22C11 or Ct-APP). D , Immunoblot analysis showed detectable amounts of the scaffolding protein JIP3/SYD in kinesin-1 immunoprecipitates (H2 IPP). Conversely, anti-JIP3 antibodies (SYd IPP) coprecipitate small but detectable amounts of KHC. Immunoprecipitations with normal mouse (NM IPP) or normal rabbit (NR IPP) IgGs were used as negative controls. Note the relative levels of JIP3/SYD compared with original protein input. E , Immunodepletion of kinesin-1 and APP from mouse brain lysate exhibits different depletion patterns. Immunodepletion of KHC from lysate with H2 comparing IPs and corresponding supernatant samples shows a gradual reduction in the level of both KHC (H2) and KLC (63-90) in the pellet (lanes 1- 4) and the supernatant (lanes 13-16) after depletion cycles. In contrast, no change in APP level could be detected (Ct-APP, lanes 1- 4 and 13-16, respectively). Similarly, a reduction in APP level was observed after depletion using APP-specific antibodies AB5352 (Ct-APP, pellet, lanes 9 -12; supernatant, lanes 21-24), but no change in the level of kinesin-1 could be detected (KHC, lanes 9 -12, 21-24; KLC, lanes 9 -12, 21-24).
Figure 2 Kinesin-1 and APP do not cofractionate or coimmunoprecipitate from brain lysate. A , Subcellular fractionation of mouse brain was performed as described previously (Morfini et al., 2002) to generate three vesicle fractions (V0, V1, and V2) and a cytosolic fraction (Cyt). Under the conditions of fractionation, KHCs and KLCs are found in all fractions, but KLCs exhibit differences in stoichiometry and isoform composition. In contrast, APP immunoreactivity is associated primarily with V0 and V1 fractions, with only trace amounts in V2 and low levels in the cytosol. V2 contains high levels of KHC, KLC1, KLC2, synaptophysin (P38), and synapsin I. This suggests that kinesin-1 and APP do not cofractionate in mouse brain. B , Immunoprecipitates of kinesin-1 from mouse brain show that Coomassie blue-stained levels of kinesin-1 heavy chain are obtained (CB), but no band corresponding to APP was seen. Immunoblots of whole-brain lysate show that kinesin-1 heavy chain (H2) is readily resolved from APP (22C11) in this gel system. These are distinguishable even when a mixture of both antibodies (H2 + 22C11) is used for immunoblotting. C , Immunoprecipitation of kinesin-1 from mouse brain using antibodies against either kinesin-1 heavy chains (SUK4 or H2) or light chains (63-90, L1, L2, or KLC-All) precipitated both KHC and KLC subunits (Pfister et al., 1989; Stenoien and Brady, 1997). Nevertheless, APP could not be detected in immunoprecipitates using kinesin-1 antibodies. Brain lysate (L) was a positive control. Negative controls, i.e., protein G beads without primary antibodies (B) or with normal mouse IgG show immunoprecipitation specificity. Similarly, kinesin-1 subunits were not detectable in immunoprecipitates with APP antibodies [Ct-APP and JH; see KHC (H2) for kinesin-1 heavy chain, KLC (63-90) for kinesin-1 light chain]. Antigens in immunoprecipitates were visualized using specific antibodies against kinesin-1 subunits (H2 or 63-90) or APP (22C11 or Ct-APP). D , Immunoblot analysis showed detectable amounts of the scaffolding protein JIP3/SYD in kinesin-1 immunoprecipitates (H2 IPP). Conversely, anti-JIP3 antibodies (SYd IPP) coprecipitate small but detectable amounts of KHC. Immunoprecipitations with normal mouse (NM IPP) or normal rabbit (NR IPP) IgGs were used as negative controls. Note the relative levels of JIP3/SYD compared with original protein input. E , Immunodepletion of kinesin-1 and APP from mouse brain lysate exhibits different depletion patterns. Immunodepletion of KHC from lysate with H2 comparing IPs and corresponding supernatant samples shows a gradual reduction in the level of both KHC (H2) and KLC (63-90) in the pellet (lanes 1- 4) and the supernatant (lanes 13-16) after depletion cycles. In contrast, no change in APP level could be detected (Ct-APP, lanes 1- 4 and 13-16, respectively). Similarly, a reduction in APP level was observed after depletion using APP-specific antibodies AB5352 (Ct-APP, pellet, lanes 9 -12; supernatant, lanes 21-24), but no change in the level of kinesin-1 could be detected (KHC, lanes 9 -12, 21-24; KLC, lanes 9 -12, 21-24).CC-BY-NC-SA · From the PDF
Figure 3 Expression and anterograde axonal transport of kinesin-1 and Trk receptor are APP independent. A , Protein extracts of sciatic nerves from wild-type mice (APP WT), mice with either homozygous or heterozygous APP depletion (Hm APP KO and Ht APP KO, respectively), and transgenic mice harboring FAD-linked APPswe (Tg2576 mice). Immunoblots for KHC, dynein, synaptophysin (Syp), neurofilament (NF), and 𝛃 -tubulin show no differences at steady-state levels between the different genotypes, indicating that fast, slow, anterograde, and retrograde axonal transport are not affected by APP expression. B , Protein extracts prepared from ligated sciatic nerve of Ht APP KO, Hm APP KO, and APP WT mice. APP accumulation is evident in the proximal ligature of sciatic nerve of APP WT mice (22C11 panel, lane 8); reduced accumulation is observed in the proximal ligature of Ht APP KOmousesciatic nerve (22C11 panel, lane 5). APP expression cannot be detected in the sciatic nerve of APP KO mice (22C11 panel, lanes 1-3). The accumulation level of Trk receptor (Trk panel), kinesin heavy chain (H2 antibodies, KHC panel), kinesin light chain (63-90 antibodies, KLC panel), and PS1 (PS1-NTF antibodies, PS1-NTF panel) at the proximal stump of the ligation site is comparable in sciatic nerve of APP-ablated and wild-type nontransgenic mice (compare lanes 2, 5, 8). I, Intact sciatic nerve; P, proximal stump of ligated sciatic nerve; D, distal stump of ligated sciatic nerve. C , Kinesin-1 expression in longitudinal sections of ligated sciatic nerve as detected by immunolabeling using anti-KHC H2 antibodies. Note kinesin-1 accumulation toward the proximal stump of the ligature.
Figure 3 Expression and anterograde axonal transport of kinesin-1 and Trk receptor are APP independent. A , Protein extracts of sciatic nerves from wild-type mice (APP WT), mice with either homozygous or heterozygous APP depletion (Hm APP KO and Ht APP KO, respectively), and transgenic mice harboring FAD-linked APPswe (Tg2576 mice). Immunoblots for KHC, dynein, synaptophysin (Syp), neurofilament (NF), and 𝛃 -tubulin show no differences at steady-state levels between the different genotypes, indicating that fast, slow, anterograde, and retrograde axonal transport are not affected by APP expression. B , Protein extracts prepared from ligated sciatic nerve of Ht APP KO, Hm APP KO, and APP WT mice. APP accumulation is evident in the proximal ligature of sciatic nerve of APP WT mice (22C11 panel, lane 8); reduced accumulation is observed in the proximal ligature of Ht APP KOmousesciatic nerve (22C11 panel, lane 5). APP expression cannot be detected in the sciatic nerve of APP KO mice (22C11 panel, lanes 1-3). The accumulation level of Trk receptor (Trk panel), kinesin heavy chain (H2 antibodies, KHC panel), kinesin light chain (63-90 antibodies, KLC panel), and PS1 (PS1-NTF antibodies, PS1-NTF panel) at the proximal stump of the ligation site is comparable in sciatic nerve of APP-ablated and wild-type nontransgenic mice (compare lanes 2, 5, 8). I, Intact sciatic nerve; P, proximal stump of ligated sciatic nerve; D, distal stump of ligated sciatic nerve. C , Kinesin-1 expression in longitudinal sections of ligated sciatic nerve as detected by immunolabeling using anti-KHC H2 antibodies. Note kinesin-1 accumulation toward the proximal stump of the ligature.CC-BY-NC-SA · From the PDF
Image 4
CC-BY-NC-SA · From the PDF
Figure 4 PS1 is not cotransported with APP in the same vesicular compartment by fast axonal transport. A , Top, Schematic diagram of sciatic nerve double ligation and nerve segments examined for protein expression. Bottom, Expression level of APP and PS1 in nerve segments at varying distances from the site of ligation in sciatic nerve of nontransgenic mice. APP expression level increases toward the site of ligation, whereas it decreases away from the distal ligature (CT15 panel, lanes 1-5). In contrast, PS1 expression level is comparable in intact sciatic nerve and nerve segments at varying distances from the site of ligation (PS1-NTF panel, lanes 1-7). B , APP and PS1 immunoreactivity in cryostat sections of the proximal and distal endsofligatedsciatic nerve. A , B , APP is detected using CT15 antibodies. Note the accumulation of APP proximal to the ligature ( A ), whereas weak immunoreactivity is observed at the distal stump( B ). C , D , PS1 immunoreactivity as detected by affinity-purified 𝛂 PS1-NTF antibodies; C , proximal stump; D , distal stump. Note that neither accumulation at the proximal stump nor reducedimmunoreactivityatthedistalstumpcanbedetected. E , Specificity of immunostaining for PS1 was confirmed using 𝛂 PS1-NTF antibodies preincubated with GST-PS1-NTF (see Materials and Methods). F , Immunostaining of mouse sciatic nerve cryostat sections using secondary antibodies only (fluorescein-conjugated goat anti-rabbit). Scale bar, 200 𝛍 m.
Figure 4 PS1 is not cotransported with APP in the same vesicular compartment by fast axonal transport. A , Top, Schematic diagram of sciatic nerve double ligation and nerve segments examined for protein expression. Bottom, Expression level of APP and PS1 in nerve segments at varying distances from the site of ligation in sciatic nerve of nontransgenic mice. APP expression level increases toward the site of ligation, whereas it decreases away from the distal ligature (CT15 panel, lanes 1-5). In contrast, PS1 expression level is comparable in intact sciatic nerve and nerve segments at varying distances from the site of ligation (PS1-NTF panel, lanes 1-7). B , APP and PS1 immunoreactivity in cryostat sections of the proximal and distal endsofligatedsciatic nerve. A , B , APP is detected using CT15 antibodies. Note the accumulation of APP proximal to the ligature ( A ), whereas weak immunoreactivity is observed at the distal stump( B ). C , D , PS1 immunoreactivity as detected by affinity-purified 𝛂 PS1-NTF antibodies; C , proximal stump; D , distal stump. Note that neither accumulation at the proximal stump nor reducedimmunoreactivityatthedistalstumpcanbedetected. E , Specificity of immunostaining for PS1 was confirmed using 𝛂 PS1-NTF antibodies preincubated with GST-PS1-NTF (see Materials and Methods). F , Immunostaining of mouse sciatic nerve cryostat sections using secondary antibodies only (fluorescein-conjugated goat anti-rabbit). Scale bar, 200 𝛍 m.CC-BY-NC-SA · From the PDF
Figure 5 Expression of BACE1 and A 𝛃 is undetectable in mouse sciatic nerve. A , Western blot analysis of A 𝛃 expression in protein extracts of stably transfected APPswe N2a cells (lane 1), APPswe N2a cells and sciatic nerve extract (lane 2), cortex (ctx) of transgenic mice harboring APPswe (lane 3), and ligated sciatic nerve of transgenic mice harboring APPswe (lanes 4 - 6). I, Intact contralateral nerve; P, segment proximal to the ligature; D, segment distal to the ligature. Accumulation of C-terminal fragments is shown, but no A 𝛃 could be detected at the proximal stump of sciatic nerve of the FAD-linked APPswe variant (lanes 4 - 6). C-terminal fragments, as well as low levels of A 𝛃 , could be detected in protein extract from the cortex of these mice using an amount of protein equivalent to that of the sciatic nerve extracts (lane 3; note 'A 𝛃 long exposure'). A 𝛃 could be detected in N2a cells stably transfected with APPswe . Addition of nerve extract to N2a cells yielded the same level of A 𝛃 as N2a alone (lanes 1 and 2, respectively). B , No specific band corresponding to BACE1 could be detected in protein extracts of ligated mouse sciatic nerve after crush injury. SN-P, Sciatic nerve segment proximal to the crush site; SN-D, sciatic nerve segment distal to the crush site. A band similar to the one observed in nontransgenic mice proximal and distal to the crush injury (BACE1 panel, lanes 2 and 3, respectively) was observed in protein extract of BACE1 KO sciatic nerve (BACE1 panel, lanes 5 and 6, respectively). To confirm our ability to detect BACE1, we examined BACE1 expression in the hippocampus of these mice. BACE1 was detectable in the hippocampus (Hipp) of nontransgenic mice (BACE1 panel, lane 1) but not in the hippocampus of BACE1 KO mice (BACE1 panel, lane 4). APP accumulated at the proximal segment of the crushed injury in the sciatic nerve of both the nontransgenic mice (APP panel, lane 2) andtheBACE1KOmice(APPpanel,lane5),confirmingtheblockadeoffastanterogradeaxonaltransport after the crush injury. As expected, increased expression of APP was observed in the hippocampus of BACE1 knock-out mice compared with nontransgenic mice (APP panel, compare lanes 4 and 1, respectively).
Figure 5 Expression of BACE1 and A 𝛃 is undetectable in mouse sciatic nerve. A , Western blot analysis of A 𝛃 expression in protein extracts of stably transfected APPswe N2a cells (lane 1), APPswe N2a cells and sciatic nerve extract (lane 2), cortex (ctx) of transgenic mice harboring APPswe (lane 3), and ligated sciatic nerve of transgenic mice harboring APPswe (lanes 4 - 6). I, Intact contralateral nerve; P, segment proximal to the ligature; D, segment distal to the ligature. Accumulation of C-terminal fragments is shown, but no A 𝛃 could be detected at the proximal stump of sciatic nerve of the FAD-linked APPswe variant (lanes 4 - 6). C-terminal fragments, as well as low levels of A 𝛃 , could be detected in protein extract from the cortex of these mice using an amount of protein equivalent to that of the sciatic nerve extracts (lane 3; note 'A 𝛃 long exposure'). A 𝛃 could be detected in N2a cells stably transfected with APPswe . Addition of nerve extract to N2a cells yielded the same level of A 𝛃 as N2a alone (lanes 1 and 2, respectively). B , No specific band corresponding to BACE1 could be detected in protein extracts of ligated mouse sciatic nerve after crush injury. SN-P, Sciatic nerve segment proximal to the crush site; SN-D, sciatic nerve segment distal to the crush site. A band similar to the one observed in nontransgenic mice proximal and distal to the crush injury (BACE1 panel, lanes 2 and 3, respectively) was observed in protein extract of BACE1 KO sciatic nerve (BACE1 panel, lanes 5 and 6, respectively). To confirm our ability to detect BACE1, we examined BACE1 expression in the hippocampus of these mice. BACE1 was detectable in the hippocampus (Hipp) of nontransgenic mice (BACE1 panel, lane 1) but not in the hippocampus of BACE1 KO mice (BACE1 panel, lane 4). APP accumulated at the proximal segment of the crushed injury in the sciatic nerve of both the nontransgenic mice (APP panel, lane 2) andtheBACE1KOmice(APPpanel,lane5),confirmingtheblockadeoffastanterogradeaxonaltransport after the crush injury. As expected, increased expression of APP was observed in the hippocampus of BACE1 knock-out mice compared with nontransgenic mice (APP panel, compare lanes 4 and 1, respectively).CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 21 Not checked · 123 Own results and interpretations

92 more claims

Create a free account to see all 144 claims and to verify the 20 references still open.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Research works printed but not linked: 1

  1. 2001, Methods Mol Biol, 164, 147

Cited by

See all 240

Metadata

Authors
Lazarov, O., Morfini, G. A., Lee, E. B., Farah, M. H., Szodorai, A., DeBoer, S. R., Koliatsos, V. E., Kins, S., Lee, V. M.-Y., Wong, P. C., Price, D. L., Brady, S. T., & Sisodia, S. S.
Affiliations
  • University of Chicago (US)
  • University of Illinois Chicago (US)
  • University of Pennsylvania (US)
  • Johns Hopkins University (US)
  • Heidelberg University (DE)
Corresponding author
Sisodia, Sangram S.
Venue
The Journal of Neuroscience
Published
2005-03-02
Volume
25
Issue
9
Pages
2386-2395
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2161021536
Cited by
239
References
48
Citations by year
2024: 4 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 6 · 2018: 3 · 2017: 1 · 2016: 8 · 2015: 12 · 2014: 20 · 2013: 13 · 2012: 20
FWCI
7.87
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Ellison Medical Foundation
  • Bristol-Myers Squibb Foundation
  • Bristol-Myers Squibb
  • Alzheimer Forschung Initiative
  • Deutsche Forschungsgemeinschaft
  • National Institutes of Health (NS23868)
  • National Institute on Aging (P01AG011542, R01AG021494, P50AG005146)
  • National Institute of Neurological Disorders and Stroke (NS 23868, R01NS041438, R01NS023320, R01NS045150, R01NS041170, R01NS023868, R01NS043408, R56NS023868)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
amyloid precursor protein, kinesin-1, axonal transport, BACE1, presenilin 1, gamma-secretase, APP proteolytic processing, sciatic nerve, membrane protein trafficking, receptor tyrosine kinase
MeSH terms
Animals, Axons, Brain, Cloning, Molecular, Glutathione Transferase, Humans, Immunohistochemistry, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Endopeptidases, Protein Binding, Recombinant Fusion Proteins, Sciatic Nerve, Protein Biosynthesis, Blotting, Western, Gene Expression, Aspartic Acid Endopeptidases, Kinesins, Amyloid beta-Protein Precursor, Sciatic Neuropathy, Receptor Protein-Tyrosine Kinases, Protein Transport, Immunoprecipitation, Green Fluorescent Proteins, Mice, Presenilin-1, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.